227 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1219)
- Addiction (16)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- Autoimmune Disorders (28)
- Blood Disorders (18)
- Bone & Muscle (10)
- Cancer (101)
- Child Development (4)
- COVID-19 (Coronavirus) (36)
- Critical Illness (1)
- Diabetes (21)
- Ear, Nose and Throat (12)
- Endocrine & Metabolic Disease (12)
- Eye (7)
- Gastrointestinal and Digestive Diseases (26)
- Hair and Skin Disorders (3)
- Headaches (5)
- Healthy Volunteers (187)
- Heart Disease (130)
- Infectious Disease (48)
- Insomnia (3)
- Kidney Disease (12)
- Liver Disease (52)
- Lung Disease (31)
- Meniere's Disease (1)
- Neurological Disorders (126)
- Nutrition (5)
- Obesity (9)
- Obstetrics & Gynecology (55)
- Pain Management (1)
- Pediatrics (98)
- Psychiatric Disorders (67)
- Rehabilitation (9)
- Stroke (7)
- Surgery (7)
- Transplant (45)
- Urology (3)
- Vascular Conditions (10)
Displaying 1 - 7 of 7
Condition: Psychiatric Disorders / Eating Disorders
Investigator: Timothy Walsh, MD
Status: Currently Recruiting
Anorexia Nervosa is a serious illness and relapse rates are high. We have shown that behavioral routines get stuck/entrenched. Our newest research, Relapse Prevention and Changing Habits (REACH+) for Anorexia Nervosa, aims to help patients minimize unhelpful routines and develop more healthful recovery-oriented behavior. Participants will complete initial…
Condition: Cancer / Gastrointestinal
Investigator: Peter Green, MD
Status: Closed
This research study is sponsored by ImmunogenX and The National Institutes of Health (NIH, Bethesda, MD). The objective of this study is to determine if the investigational product (latiglutenase) will help decrease symptoms in subjects with celiac disease while maintaining a gluten-free diet while undergoing periodic gluten exposure. In addition, this…
Condition: Cancer / Gastrointestinal
Investigator: Yoanna Pumpalova, MD
Status: Closed
This study evaluates whether the addition of immune therapy to usual FOLFOX chemotherapy in patients with deficient DNA mismatch repair stage III colon cancer can improve your outcome compared to FOLFOX alone. The immune therapy drug, atezolizumab, may allow your body's immune system to more effectively kill cancer cells in your body. One of the…
Condition: Psychiatric Disorders / Eating Disorders
Investigator: Kelsey Hagan, PhD
Status: Closed
People with bulimia nervosa engage in risky behaviors more often than people without this disorder. We are researching the neurobiological underpinnings of risky decision-making in bulimia nervosa. As a participant in this study, you would: (1) complete a series of questionnaires and interviews, (2) complete an MRI scan (no radiation), and (3) complete…
Condition: Psychiatric Disorders / Eating Disorders
Investigator: Kelsey Hagan, PhD
Status: Closed
People with bulimia nervosa engage in risky behaviors more often than people without this disorder. We are researching the neurobiological underpinnings of risky decision-making in bulimia nervosa. As a participant in this study, your teen would: (1) complete a series of questionnaires and interviews, (2) complete an MRI scan (no radiation), and (3)…
Condition: Addiction / Cocaine
Investigator: Frances Levin, MD
Status: Closed
This study will test a computer-based behavioral intervention to decrease cocaine use. Those who fail to achieve cocaine abstinence after the first 4 weeks while receiving the behavioral treatment will continue the behavioral treatment and be randomly assigned to one of two groups (one group will receive Adderall-XR (MAS-ER) and the other group will receive…
Condition: Addiction / Cocaine
Investigator: Frances Levin, MD
Status: Closed
The study is a two group outpatient study, one group receiving medications (Adderall-XR and topiramate) and one group receiving a placebo (inactive sugar pill). The study is looking at the safety and effectiveness of Adderall-XR (MAS-ER) and topiramate in the treatment of cocaine dependence. It is a 14-week trial that requires patients to attend visits 3…